ํBSLN โข SWX
add
Basilea Pharmaceutica AG Allschwil
์ ์ผ ์ข
๊ฐ
CHFย 54.20
์ผ์ผ ๋ณ๋ํญ
CHFย 51.90 - CHFย 53.40
52์ฃผ ๋ณ๋ํญ
CHFย 37.50 - CHFย 59.70
์๊ฐ์ด์ก
7.02์ต CHF
ํ๊ท ๊ฑฐ๋๋
3.98๋ง
์ฃผ๊ฐ์์ต๋ฅ
10.07
๋ฐฐ๋น์์ต๋ฅ
-
๊ธฐ๋ณธ ๊ฑฐ๋์
SWX
์์ฅ ๋ด์ค
์ฌ๋ฌด
์์ต๊ณ์ฐ์
์์ต
์์ด์ต
| (CHF) | 2025๋ 6์info | ์ ๋ ๋๋น ๋ณ๋ |
|---|---|---|
์์ต | 5198.00๋ง | 36.26% |
์ด์๋น | 852.65๋ง | 13.23% |
์์ด์ต | 790.10๋ง | -23.80% |
์์ด์ต๋ฅ | 15.20 | -44.08% |
์ฃผ๋น ์์ต | โ | โ |
EBITDA | 1254.95๋ง | 147.17% |
์ ํจ ์ธ์จ | 18.31% | โ |
๋์ฐจ๋์กฐํ
์ด์์ฐ
์ด๋ถ์ฑ
| (CHF) | 2025๋ 6์info | ์ ๋ ๋๋น ๋ณ๋ |
|---|---|---|
ํ๊ธ ๋ฐ ๋จ๊ธฐ ํฌ์ | 1.28์ต | 103.87% |
์ด์์ฐ | 2.49์ต | 31.90% |
์ด๋ถ์ฑ | 1.46์ต | -15.24% |
์ด์๊ธฐ์๋ณธ | 1.03์ต | โ |
๋ฐํ ์ฃผ์ | 1228.33๋ง | โ |
์ฃผ๊ฐ์์์ฐ๋น์จ | 6.45 | โ |
์ด์์ฐ์ด์ต๋ฅ | 12.25% | โ |
์๋ณธ์ด์ต๋ฅ | 15.24% | โ |
ํ๊ธ ํ๋ฆ
์ํ๊ธํ๋ฆ
| (CHF) | 2025๋ 6์info | ์ ๋ ๋๋น ๋ณ๋ |
|---|---|---|
์์ด์ต | 790.10๋ง | -23.80% |
์์
ํ๊ธ ํ๋ฆ | 1152.80๋ง | 28.66% |
ํฌ์ ํ๊ธ ํ๋ฆ | -20.70๋ง | -258.62% |
์๊ธ ์กฐ๋ฌ ํ๊ธ ํ๋ฆ | -723.50๋ง | -10.11% |
์ํ๊ธํ๋ฆ | 408.05๋ง | 58.53% |
์์ฌ ํ๊ธ ํ๋ฆ | 889.29๋ง | 135.55% |
์ ๋ณด
Basilea Pharmaceutica is a biopharmaceutical company based in Allschwil near Basel, Switzerland. Basilea was spun off from F. Hoffmann-La Roche in 2000 and has been listed as an independent company on the Swiss stock exchange since March 2004. The company's subsidiary is Basilea Pharmaceutica International AG, Allschwil, which is also based in Allschwil, Switzerland, and in which the company's operating activities are bundled. Wikipedia
์ค๋ฆฝ
2000
์น์ฌ์ดํธ
์ง์ ์
180
